Quantcast

Latest Proteasome inhibitor Stories

2010-07-23 16:02:00

EMERYVILLE, Calif., July 23 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a teleconference and webcast on Monday, July 26, 2010, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to provide a clinical update on carfilzomib. Interested parties may access a live webcast of the presentation on the company's website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar or by dialing 847-619-6547 and using the passcode 27571112. A...

2010-07-12 14:11:11

Findings by the John Theurer Cancer Center may lead to more targeted clinical trials and therapies A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib (VELCADE®), the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma. The study also provides preliminary evidence for which patients might benefit most from bortezomib. Additionally, researchers...

2010-06-14 01:40:00

EMERYVILLE, Calif., June 14 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a teleconference and webcast on Monday, June 14, 2010, at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) to provide an update on Nexavar® (sorafenib) tablets. Interested parties may access a live webcast of the presentation on the company's website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar or by dialing 847-619-6547 and using...

2010-06-08 15:00:00

EMERYVILLE, Calif., June 8 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at Goldman Sachs 31st Annual Global Healthcare Conference on Tuesday, June 15, 2010 at 4:55 p.m. Eastern Time (1:55 p.m. Pacific Time). Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar It is recommended that listeners log on 15 minutes early in order to register and...

2010-06-08 08:00:00

EMERYVILLE, Calif., June 8 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 15th Congress of European Hematology, organized by The European Hematology Association (EHA), June 10-13, 2010 in Barcelona, Spain. Presentations will highlight data from the carfilzomib development program in patients with relapsed and/or refractory multiple...

2010-06-05 16:30:00

EMERYVILLE, Calif., June 5 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced interim results from an ongoing Phase 2 study, known as the 004 study. Carfilzomib, a selective, next-generation proteasome inhibitor, demonstrated encouraging overall response rates (ORR), tolerability and durable disease control when administered as a single-agent in patients with relapsed and/or refractory multiple myeloma. In 53 evaluable patients who had not been previously...

2010-06-04 14:00:00

EMERYVILLE, Calif., June 4 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by...

2010-06-01 08:00:00

EMERYVILLE, Calif., June 1 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the initiation of a Phase 1 study of ONX 0912, an oral proteasome inhibitor, in patients with advanced refractory or recurrent solid tumors. "Based on insights gained from our ongoing carfilzomib development program and ONX 0912's favorable preclinical profile - anti-tumor activity, safety and biodistribution - we believe ONX 0912 may have the potential to expand the use of...

2010-05-20 17:01:00

EMERYVILLE, Calif., May 20 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 2010 in Chicago, IL. Presentations will highlight data from the carfilzomib development program in patients with relapsed/refractory multiple myeloma and solid tumors. Each presentation...

2010-02-02 07:00:00

EMERYVILLE, Calif., Feb. 2 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 international randomized trial. This pivotal trial, which is expected to begin in the first half of 2010, will enroll patients with relapsed multiple myeloma following treatment with one to three prior regimens. It is designed to evaluate the...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related